Share on: 
Website: Aravive
Business Area(s): 

Aravive (formerly Versartis) is developing treatments designed to halt progression of life-threatening diseases, including cancer and fibrosis. Their approach draws on novel insights into targeting signaling pathways that drive the activation, migration and invasion of abnormal cells into healthy tissues. Aravive’s lead product candidate AVB-500 is an ultra-high affinity decoy protein that starves the GAS6/AXL signaling pathway of its signal by capturing circulating and bound GAS6, thereby potentially stopping the activation, migration and invasion of aberrant cells. In studies to date, AVB-500 has demonstrated a favorable safety profile as a potential non-toxic drug that halts disease progression by effectively blocking GAS6/AXL signaling.

Career Page(s): 
Houston TX
United States
Palo Alto CA
United States